PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.
Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Ruth Vera(Complejo Hospitalario de Navarra), Carles Pericay(University Hospital Mútua de Terrassa), María José Safont(Hospital General Universitario De Valencia), Monique Maas(The Netherlands Cancer Institute), Nuria Rodríguez Salas(Hospital Universitario La Paz), Joan Maurel(Breast Cancer Research Foundation), Ferrán Losa, Jorge Aparicio(Hospital Universitari i Politècnic La Fe), M. Tobeña(Hospital de Sant Pau), Jaume Capdevila(Vall d'Hebron Institut de Recerca), Juan Ramón Ayuso(Hospital Clínic de Barcelona), Manuel Valladares(American Society of Clinical Oncology), Javier Gállego(Hospital General Universitario de Elche)
Cited by 0
Related Papers
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
|The Oncologist|2012|213
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
|The Lancet. Gastroenterology & hepatology|2018|188